Treatment of dyslipidemia in patients with type 2 diabetes

Lipids in Health and Disease

Volumn 9, Issue , 2010, Pages

  Vijayaraghavan, Krishnaswami ^a  

^a Virginia G Piper Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; BILE ACID SEQUESTRANT; COLESEVELAM; EZETIMIBE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINIC ACID; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONSTIPATION; DYSLIPIDEMIA; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY FUNCTION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; BLOOD; CLINICAL TRIAL (TOPIC); FEMALE; INSULIN RESISTANCE; MALE; METABOLISM; PATHOPHYSIOLOGY; PREVALENCE; RISK FACTOR;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INSULIN RESISTANCE; LIPOPROTEINS; MALE; PREVALENCE; RISK FACTORS; TRIGLYCERIDES;

EID: 78650256519     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-9-144     Document Type: Review

References (92)

1. National diabetes fact sheet. Centers for Disease Control and Prevention, http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2007.pdf
2. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex (UKPDS 27). United Kingdom Prospective Diabetes Study, Diabetes Care 1997 20 1683 1687 10.2337/diacare.20.11.1683 9353608
3. Diabetes and cardiovascular disease. The Framingham study. WB Kannel DL McGee, JAMA 1979 241 2035 2038 10.1001/jama.241.19.2035 430798
4. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. SH Saydah J Fradkin CC Cowie, JAMA 2004 291 335 342 10.1001/jama.291.3.335 14734596
5. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. IM Stratton AI Adler HA Neil DR Matthews SE Manley CA Cull D Hadden RC Turner RR Holman, BMJ 2000 321 405 412 10.1136/bmj.321.7258.405 10938048
6. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). RC Turner H Millns HA Neil IM Stratton SE Manley DR Matthews RR Holman, BMJ 1998 316 823 828 9549452
7. Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials. JA Farmer, Curr Diab Rep 2008 8 71 77 10.1007/s11892-008-0013-2 18367002
8. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. DC Goff Jr HC Gerstein HN Ginsberg WC Cushman KL Margolis RP Byington JB Buse S Genuth JL Probstfield DG Simons-Morton, Am J Cardiol 2007 99 4i 20i 17599424
9. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. JD Brunzell M Davidson CD Furberg RB Goldberg BV Howard JH Stein JL Witztum, Diabetes Care 2008 31 811 822 10.2337/dc08-9018 18375431
10. Standards of medical care in diabetes-2009. American Diabetes Association, Diabetes Care 2009 32 Suppl 1 13 S61 19118286 10.2337/dc09-S013
11. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. J Stamler O Vaccaro JD Neaton D Wentworth, Diabetes Care 1993 16 434 444 10.2337/diacare.16.2.434 8432214
12. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. SM Grundy JI Cleeman CN Merz HB Brewer Jr LT Clark DB Hunninghake RC Pasternak SC Smith Jr NJ Stone, Circulation 2004 110 227 239 10.1161/01.CIR.0000133317.49796.0E 15249516
13. Diabetic dyslipidaemia. M Adiels SO Olofsson MR Taskinen J Boren, Curr Opin Lipidol 2006 17 238 246 10.1097/01.mol.0000226115.97436.c0 16680028
14. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. M Adiels SO Olofsson MR Taskinen J Boren, Arterioscler Thromb Vasc Biol 2008 28 1225 1236 10.1161/ATVBAHA.107. 160192 18565848
15. Type 2 diabetes as a lipid disorder. MR Taskinen, Curr Mol Med 2005 5 297 308 10.2174/1566524053766086 15892649
16. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. WT Garvey S Kwon D Zheng S Shaughnessy P Wallace A Hutto K Pugh AJ Jenkins RL Klein Y Liao, Diabetes 2003 52 453 462 10.2337/diabetes.52.2.453 12540621
17. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. AJ Krentz, Diabetes Obes Metab 2003 5 Suppl 1 19 S27 10.1046/j.1462-8902.2003.0310.x 14984018
18. Management of dyslipidemia in diabetes. MP Solano RB Goldberg, Cardiol Rev 2006 14 125 135 10.1097/01.crd.0000188034.76283.5e 16628021
19. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. United Kingdom Prospective Diabetes Study, Lancet 1998 352 837 853 10.1016/S0140-6736(98) 07019-6 9742976
20. Role of lipases, lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus. R de Vries SE Borggreve RP Dullaart, Clin Lab 2003 49 601 613 14651331
21. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. MJ Forrest D Bloomfield RJ Briscoe PN Brown AM Cumiskey J Ehrhart JC Hershey WJ Keller X Ma HE McPherson E Messina LB Peterson W Sharif-Rodriguez PK Siegl PJ Sinclair CP Sparrow AS Stevenson SY Sun C Tsai H Vargas M Walker SH West V White RF Woltmann, Br J Pharmacol 2008 154 1465 1473 10.1038/bjp.2008.229 18536749
22. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. D Bloomfield GL Carlson A Sapre D Tribble JM McKenney TW Littlejohn CM Sisk Y Mitchel RC Pasternak, Am Heart J 2009 157 352 360 e352 10.1016/j.ahj.2008.09.022 19185645
23. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis. D Masson, Curr Opin Investig Drugs 2009 10 980 987 19705341
24. Molecular mechanisms of insulin resistance that impact cardiovascular biology. CC Wang ML Goalstone B Draznin, Diabetes 2004 53 2735 2740 10.2337/diabetes.53.11.2735 15504952
25. Approaches to prevention of cardiovascular complications and events in diabetes mellitus. S Coccheri, Drugs 2007 67 997 1026 10.2165/00003495- 200767070-00005 17488145
26. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. S Yusuf P Sleight J Pogue J Bosch R Davies G Dagenais, N Engl J Med 2000 342 145 153 10.1056/NEJM200001203420301 10639539
27. Prevalence and control of dyslipidemia among persons with diabetes in the United States. MJ Jacobs T Kleisli JR Pio S Malik GJ L'Italien RS Chen ND Wong, Diabetes Res Clin Pract 2005 70 263 269 10.1016/j.diabres.2005.03.032 15890427
28. Prevalence of self-reported diagnosis of diabetes mellitus and associated risk factors in a national survey in the US population: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes). HE Bays DD Bazata NG Clark JR Gavin AJ Green SJ Lewis ML Reed W Stewart RH Chapman KM Fox S Grandy, BMC Public Health 2007 7 277 10.1186/1471-2458-7-277 17915014
29. European Action on Secondary Prevention through Intervention to Reduce Events. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group, Eur Heart J 1997 18 1569 1582 9347267
30. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Cholesterol Education Program Expert Panel, JAMA 2001 285 2486 2497 10.1001/jama.285.19.2486 11368702
31. Small, dense, low-density lipoprotein and atherosclerosis. HR Superko, Curr Atheroscler Rep 2000 2 226 231 10.1007/s11883-000-0024-1 11122748
32. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. HM Colhoun DJ Betteridge PN Durrington GA Hitman HA Neil SJ Livingstone MJ Thomason MI Mackness V Charlton-Menys JH Fuller, Lancet 2004 364 685 696 10.1016/S0140-6736(04)16895-5 15325833
33. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. R Collins J Armitage S Parish P Sleigh R Peto, Lancet 2003 361 2005 2016 10.1016/S0140-6736(03)12475-0 12814710
34. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). PS Sever NR Poulter B Dahlof H Wedel R Collins G Beevers M Caulfield SE Kjeldsen A Kristinsson GT McInnes J Mehlsen M Nieminen E O'Brien J Ostergren, Diabetes Care 2005 28 1151 1157 10.2337/diacare.28.5.1151 15855581 (Pubitemid 40616627)
35. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. J Shepherd P Barter R Carmena P Deedwania JC Fruchart S Haffner J Hsia A Breazna J LaRosa S Grundy D Waters, Diabetes Care 2006 29 1220 1226 10.2337/dc05-2465 16731999
36. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. PM Kearney L Blackwell R Collins A Keech J Simes R Peto J Armitage C Baigent, Lancet 2008 371 117 125 10.1016/S0140-6736(08)60761-8 18191683
37. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). RH Knopp M d'Emden JG Smilde SJ Pocock, Diabetes Care 2006 29 1478 1485 10.2337/dc05-2415 16801565
38. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. M Briel I Ferreira-Gonzalez JJ You PJ Karanicolas EA Akl P Wu B Blechacz D Bassler X Wei A Sharman I Whitt S Alves da Silva Z Khalid AJ Nordmann Q Zhou SD Walter N Vale N Bhatnagar C O'Regan EJ Mills HC Bucher VM Montori GH Guyatt, BMJ 2009 338 92 10.1136/bmj.b92 19221140
39. Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. N Sattar K Williams AD Sniderman R D'Agostino Jr SM Haffner, Circulation 2004 110 2687 2693 10.1161/01.CIR.0000145660.60487.94 15492304
40. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. AD Sniderman CD Furberg A Keech JE Roeters van Lennep J Frohlich I Jungner G Walldius, Lancet 2003 361 777 780 10.1016/S0140-6736(03) 12663-3 12620753
41. Low-density lipoprotein particle number and risk for cardiovascular disease. WC Cromwell JD Otvos, Curr Atheroscler Rep 2004 6 381 387 10.1007/s11883-004-0050-5 15296705
42. The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment. M Andrikoula IF McDowell, Diabetes Obes Metab 2008 10 271 278 10.1111/j.1463-1326.2007.00714.x 18333887
43. Apo-B/AI ratio identifies cardiovascular risk in childhood: the Australian Aboriginal Birth Cohort study. EA Sellers GR Singh SM Sayers, Diab Vasc Dis Res 2009 6 94 99 10.1177/1479164109336046 20368199
44. Redefining quality-implications of recent clinical trials. HM Krumholz TH Lee, N Engl J Med 2008 358 2537 2539 10.1056/NEJMp0803740 18539915
45. The great debate of 2008-how low to go in preventive cardiology? ED Peterson TY Wang, JAMA 2008 299 1718 1720 10.1001/jama.299.14.1718 18398086
46. Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. EA Stein A Sniderman P Laskarzewski, Am J Cardiol 2005 96 36K 43K discussion 34K-35K 10.1016/j.amjcard.2005.08.006 16291013
47. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. CM Ballantyne M Bertolami HR Hernandez Garcia D Nul EA Stein P Theroux R Weiss VA Cain JS Raichlen, Am Heart J 2006 151 975 971 e979
48. Pharmacologic treatment of type 2 diabetic dyslipidemia. YS Moon ML Kashyap, Pharmacotherapy 2004 24 1692 1713 10.1592/phco.24.17.1692.52340 15585439
49. High-dose atorvastatin therapy achieves 25% reduction in CV events in TNT substudy of diabetic patients. Cardiovasc J S Afr 2006 17 206 207 17001426
50. The effect of high dose atorvastatin therapy on lipids and lipoprotein subfractions in overweight patients with type 2 diabetes. JM Lawrence J Reid GJ Taylor C Stirling JP Reckless, Atherosclerosis 2004 174 141 149 10.1016/j.atherosclerosis.2004.01.016 15135263
51. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. RW Nesto, Am J Cardiovasc Drugs 2005 5 379 387 10.2165/00129784-200505060-00005 16259526
52. Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. B Lauring V Dishy WL Luo O Laterza J Patterson J Cote A Chao P Larson M Gutierrez JA Wagner E Lai, J Clin Pharmacol 2009 49 1426 1435 10.1177/0091270009339593 19833861
53. Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. S Shah R Ceska B Gil-Extremera JF Paolini H Giezek K Vandormael A Mao C McCrary Sisk D Maccubbin, Int J Clin Pract 2010 64 727 738 10.1111/j.1742-1241.2010.02370.x 20518948
54. Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin in patients with dyslipidemia [abstract 683]. G Gleim N Liu S Thompson-Bell, Circulation 2007 116 127 10.1161/CIRCULATIONAHA.107.187674
55. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. CM Ballantyne J Houri A Notarbartolo L Melani LJ Lipka R Suresh S Sun AP LeBeaut PT Sager EP Veltri, Circulation 2003 107 2409 2415 10.1161/01.CIR.0000068312. 21969.C8 12719279
56. After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes? H Colhoun, Lancet 2005 366 1829 1831 10.1016/S0140-6736(05)67668-4 16310536
57. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. A Keech RJ Simes P Barter J Best R Scott MR Taskinen P Forder A Pillai T Davis P Glasziou P Drury YA Kesaniemi D Sullivan D Hunt P Colman M d'Emden M Whiting C Ehnholm M Laakso, Lancet 2005 366 1849 1861 10.1016/S0140-6736(05) 67667-2 16310551
58. Effects of combination lipid therapy in type 2 diabetes mellitus. HN Ginsberg MB Elam LC Lovato JR Crouse LA Leiter P Linz WT Friedewald JB Buse HC Gerstein J Probstfield RH Grimm F Ismail-Beigi JT Bigger DC Goff Jr WC Cushman DG Simons-Morton RP Byington, N Engl J Med 2010 362 1563 1574 10.1056/NEJMoa1001282 20228404
59. Effects of fibrates on metabolism of statins in human hepatocytes. T Prueksaritanont C Tang Y Qiu L Mu R Subramanian JH Lin, Drug Metab Dispos 2002 30 1280 1287 10.1124/dmd.30.11.1280 12386136
60. Glucophage (metformin hydrochloride tablets) prescribing information. Bristol-Myers Squibb Company: Princeton, NJ 2009 http://packageinserts.bms.com/ pi/pi-glucophage.pdf
61. ACTOS (pioglitazone hydrochloride tablets) prescribing information. Takeda Pharmaceuticals America, Inc.: Deerfield, IL 2009 http://www.actos.com/ actospro/prescribinginfo.aspx
62. Avandia (rosiglitazone maleate tablets) prescribing information. GlaxoSmithKline: Research Triangle Park, NC 2008 http://us.gsk.com/products/ assets/us-avandia.pdf
63. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. MA Khan JV St Peter JL Xue, Diabetes Care 2002 25 708 711 10.2337/diacare.25.4.708 11919129
64. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. MA Deeg JB Buse RB Goldberg DM Kendall AJ Zagar SJ Jacober MA Khan AT Perez MH Tan, Diabetes Care 2007 30 2458 2464 10.2337/dc06-1903 17595355
65. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia. M Comaschi A Corsi C Di Pietro A Bellatreccia S Mariz, Nutr Metab Cardiovasc Dis 2008 18 373 379 10.1016/j.numecd.2007.04.003 17919894
66. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. MS Kipnes A Krosnick MS Rendell JW Egan AL Mathisen RL Schneider, Am J Med 2001 111 10 17 10.1016/S0002-9343(01)00713-6 11448655
67. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. P Berhanu MS Kipnes MA Khan AT Perez SF Kupfer RC Spanheimer S Demissie PR Fleck, Diab Vasc Dis Res 2006 3 39 44 10.3132/dvdr.2006.005 16784180
68. Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. GM Reaven CK Lardinois MS Greenfield HC Schwartz HJ Vreman, Diabetes Care 1990 13 Suppl 3 32 36 2209341
69. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors. CA Reasner, J Cardiovasc Pharmacol 2008 52 136 144 10.1097/FJC.0b013e31817ffe5a 18670366
70. Endocrine functions of bile acids. SM Houten M Watanabe J Auwerx, EMBO J 2006 25 1419 1425 10.1038/sj.emboj.7601049 16541101
71. The 'forgotten' bile acid sequestrants: is now a good time to remember? HE Bays RB Goldberg, Am J Ther 2007 14 567 580 10.1097/MJT.0b013e31815a69fc 18090882
72. Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway. AB Goldfine, Curr Opin Cardiol 2008 23 502 511 10.1097/HCO.0b013e32830c6c37 18670263
73. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. W Insull Jr P Toth W Mullican D Hunninghake S Burke JM Donovan MH Davidson, Mayo Clin Proc 2001 76 971 982 10.4065/76.10.971 11605698
74. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. D Hunninghake W Insull Jr P Toth D Davidson JM Donovan SK Burke, Atherosclerosis 2001 158 407 416 10.1016/S0021-9150(01)00437-3 11583720
75. Welchol (colesevelam HCl) prescribing information. Daiichi Sankyo, Inc: Parsippany, NJ 2009 http://www.welchol.com/pdf/Welchol-PI.pdf
76. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. FJ Zieve MF Kalin SL Schwartz MR Jones WL Bailey, Clin Ther 2007 29 74 83 10.1016/j.clinthera.2007.01.003 17379048
77. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. HE Bays RB Goldberg KE Truitt MR Jones, Arch Intern Med 2008 168 1975 1983 10.1001/archinte.168.18. 1975 18852398
78. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. VA Fonseca J Rosenstock AC Wang KE Truitt MR Jones, Diabetes Care 2008 31 1479 1484 10.2337/dc08-0283 18458145
79. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. RB Goldberg VA Fonseca KE Truitt MR Jones, Arch Intern Med 2008 168 1531 1540 10.1001/archinte.168.14.1531 18663165
80. Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes. RS Rosenson SL Abby MR Jones, Atherosclerosis 2009 204 342 344 10.1016/j.atherosclerosis.2008.09.026 18996525
81. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. B Staels F Kuipers, Drugs 2007 67 1383 1392 10.2165/00003495-200767100-00001 17600387
82. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. T Claudel B Staels F Kuipers, Arterioscler Thromb Vasc Biol 2005 25 2020 2030 10.1161/01.ATV.0000178994.21828.a7 16037564
83. A review of bile acid sequestrants: potential mechanism(s) for glucose-lowering effects in type 2 diabetes mellitus. B Staels, Postgrad Med 2009 121 25 30 10.3810/pgm.2009.05.suppl53.290 19494475
84. Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. T Suzuki K Oba Y Igari N Matsumura K Watanabe S Futami-Suda H Yasuoka M Ouchi K Suzuki Y Kigawa H Nakano, J Nippon Med Sch 2007 74 338 343 10.1272/jnms.74.338 17965527
85. Colesevelam HCl improves glucose metabolism and increases plasma glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide concentrations in subjects with type 2 diabetes. C Beysen KC Deines EL Tsang EJ Murphy M Chan JM Edmonds RA Neese MK Hellerstein, European Association for the Study of Diabetes Annual Meeting Vienna, Austria 2009
86. Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. JA Papadakis ES Ganotakis IA Jagroop DP Mikhailidis AF Winder, Am J Hypertens 1999 12 673 681 10.1016/S0895-7061(99)00049-7 10411364
87. Statins: another class of antihypertensive agents? HJ Milionis EN Liberopoulos A Achimastos MS Elisaf DP Mikhailidis, J Hum Hypertens 2006 20 320 335 10.1038/sj.jhh.1002001 16511505
88. Dyslipidemia and the progression of renal disease in chronic renal failure patients. A Cases E Coll, Kidney Int Suppl 2005 87 S93 10.1111/j.1523-1755.2005.09916.x 16336584
89. Cholesterol and the risk of renal dysfunction in apparently healthy men. ES Schaeffner T Kurth GC Curhan RJ Glynn KM Rexrode C Baigent JE Buring JM Gaziano, J Am Soc Nephrol 2003 14 2084 2091 12874462
90. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. M Ravid D Brosh D Ravid-Safran Z Levy R Rachmani, Arch Intern Med 1998 158 998 1004 10.1001/archinte.158.9.998 9588433
91. Cardiac disease in diabetic end-stage renal disease. RN Foley BF Culleton PS Parfrey JD Harnett GM Kent DC Murray PE Barre, Diabetologia 1997 40 1307 1312 10.1007/s001250050825 9389423
92. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. M Tonelli L Moye FM Sacks T Cole GC Curhan, J Am Soc Nephrol 2003 14 1605 1613 10.1097/01.ASN. 0000068461.45784.2F 12761262